Full-Service Clinical Trials in Central and Eastern Europe

OCT is starting a new trial in 10 sites in Russia within a big diabetes clinical trials program for the US company.

Repeat business for OCT: the company is planning to initiate the second protocol for the Italian company. This will be the study in breast cancer.

OCT successfully finished the study in breast cancer having enrolled 166 patients in 10 sites within 6 months.

OCT signed the contract to increase the number of countries from 5 to 7 in erectile dysfunction study for the Russian Pharma.

OCT has been contracted to increase the number of sites from 34 up to 40 in ovarian cancer trial.

OCT has been chosen to conduct hypertension plus LVH study for Menarini Group, 62 patients already enrolled, and hepatic cirrhosis study with 19 sites for the UK Pharma.

Dmitry Shaikin, OCT CEO, outlined how to set up a successful investigator’s meeting in Eastern Europe.

OCT’s Clinical Research Associates are starting working on cardiology and hepatology trials in St. Petersburg and Moscow sites, Russia.

OCT starts collaboration with one of the world largest pharmaceutical companies providing the partner with CRAs in Baltic States at outsourcing FTE basis.

OCT is glad to announce that the company is starting the trial in neovascular macular degeneration with 3 sites and 15 patients to be enrolled in Baltic States.

OCT is starting the trial in diabetes mellitus with 6 sites and 60 patients to be enrolled in Russia.

OCT announces the opening of the new office in Minsk, Belarus. This will be the 6th office of OCT in Eastern Europe. The main pluses of the region are low competition among the ongoing trials, relatively high population (amounting about 10 million people) concentrated in big cities, centralized healthcare system, large therapeutic hospitals, others.

OCT has won the urology trial covering 5 countries, 300 patients to be enrolled. The study will be conducted for one of the largest Russian pharmaceutical companies. This will be a full-service project including all the activities from writing the protocol to data management and statistical analysis.

OCT informs you about opening a new office in Riga, Latvia. This is the 5th clinical operations’ office of the company within headquarters in St. Petersburg and local offices in Moscow (Russia), Kiev (Ukraine), and Sofia (Bulgaria). Opening the office in Riga allows to monitor all three Baltic countries, including Latvia, Lithuania, and Estonia.

OCT is awarded with a big oncology trial in ovarian cancer patients. The trial will include 34 sites in 5 countries (Russia, Ukraine, Bulgaria, Latvia and Lithuania) and over 300 patients in total.